Pandemic Pushes Rx To OTC Switches

The U.S. Rx-to-OTC market has grown into a $13,807 million ($13.8 billion) market, according to 2021 estimates by leading medical market researcher Kalorama Information in the new report The Market for Rx-to-OTC Switches, 8th Edition. This has mainly been due to factors such as patent expirations, increasing competitiveness with the pharmaceutical environment, the FDA willingness […]

COVID-19: A Vaccine Solution?

Not since the Swine Flu epidemic of 2009 has there been this amount of emphasis on vaccines and vaccine development.  This new infectious disease threat with no anti-viral, nor vaccine is causing significant concern among healthcare providers, governments and the public.  Last-resort measures such as school closings and curfews in place in the United States […]

Pfizer Zirabev Approval Sign of Growth Market for Biosimilars, Challenges for Cancer Drug Brands

News of an approval of a biosimilar for a major Roche cancer drug is, we think, evidence that U.S. biosimilars are a growth market opportunity.   At the same time, the approval is a growth limiter for booming cancer drug markets.  Pfizer Inc confirmed Friday that the the FDA approved its biosimilar to Avastin. Pfizer’s Zirabev […]